These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 710026)

  • 1. Disposition of metformin (N,N-dimethylbiguanide) in man.
    Sirtori CR; Franceschini G; Galli-Kienle M; Cighetti G; Galli G; Bondioli A; Conti F
    Clin Pharmacol Ther; 1978 Dec; 24(6):683-93. PubMed ID: 710026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of metformin.
    Scheen AJ
    Clin Pharmacokinet; 1996 May; 30(5):359-71. PubMed ID: 8743335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of metformin after intravenous and oral administration to man.
    Pentikäinen PJ; Neuvonen PJ; Penttilä A
    Eur J Clin Pharmacol; 1979 Sep; 16(3):195-202. PubMed ID: 499320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of metformin renal tubular secretion by cimetidine in man.
    Somogyi A; Stockley C; Keal J; Rolan P; Bochner F
    Br J Clin Pharmacol; 1987 May; 23(5):545-51. PubMed ID: 3593625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma biguanide levels are correlated with metabolic effects in diabetic patients.
    Marchetti P; Benzi L; Cecchetti P; Giannarelli R; Boni C; Ciociaro D; Ciccarone AM; Di Cianni G; Zappella A; Navalesi R
    Clin Pharmacol Ther; 1987 Apr; 41(4):450-4. PubMed ID: 3829580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products.
    Pentikäinen PJ
    Int J Clin Pharmacol Ther Toxicol; 1986 Apr; 24(4):213-20. PubMed ID: 3710634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy.
    Vecchio S; Giampreti A; Petrolini VM; Lonati D; Protti A; Papa P; Rognoni C; Valli A; Rocchi L; Rolandi L; Manzo L; Locatelli CA
    Clin Toxicol (Phila); 2014 Feb; 52(2):129-35. PubMed ID: 24283301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The status of metformin in Canada.
    Lucis OJ
    Can Med Assoc J; 1983 Jan; 128(1):24-6. PubMed ID: 6847752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects.
    Robert F; Fendri S; Hary L; Lacroix C; Andréjak M; Lalau JD
    Diabetes Metab; 2003 Jun; 29(3):279-83. PubMed ID: 12909816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function.
    Duong JK; Kroonen MYAM; Kumar SS; Heerspink HL; Kirkpatrick CM; Graham GG; Williams KM; Day RO
    Eur J Clin Pharmacol; 2017 Aug; 73(8):981-990. PubMed ID: 28451709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction.
    Chan K; Tse J; Jennings F; Orme ML
    J Clin Pharmacol; 1987 Jul; 27(7):516-22. PubMed ID: 3655004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interaction between telithromycin and metformin in diabetes mellitus rats.
    Lee JH; Kang HE; Lee MG
    Xenobiotica; 2010 Mar; 40(3):217-24. PubMed ID: 20039777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactate levels and risk of lactic acidosis with metformin in diabetic kidney disease patients.
    Bipi PK; George J; Gomathy S; Gracious N; Kumar S; Mohandas MK
    Saudi J Kidney Dis Transpl; 2017; 28(6):1356-1361. PubMed ID: 29265047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral and intravenous bretylium disposition.
    Anderson JL; Patterson E; Wagner JG; Stewart JR; Behm HL; Lucchesi BR
    Clin Pharmacol Ther; 1980 Oct; 28(4):468-78. PubMed ID: 7408407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin-associated lactic acidosis treated with continuous renal replacement therapy.
    Alivanis P; Giannikouris I; Paliuras C; Arvanitis A; Volanaki M; Zervos A
    Clin Ther; 2006 Mar; 28(3):396-400. PubMed ID: 16750454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of metformin accumulation in metformin-associated lactic acidosis.
    Lalau JD; Lacroix C; Compagnon P; de Cagny B; Rigaud JP; Bleichner G; Chauveau P; Dulbecco P; Guérin C; Haegy JM
    Diabetes Care; 1995 Jun; 18(6):779-84. PubMed ID: 7555503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure.
    Adam WR; O'Brien RC
    Diabet Med; 2014 Sep; 31(9):1032-8. PubMed ID: 24909998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.
    Nilsen OG; Aasarød K; Widerøe TE; Guentert TW
    Pharmacol Toxicol; 2001 Nov; 89(5):265-72. PubMed ID: 11881981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver uptake of biguanides in rats.
    Sogame Y; Kitamura A; Yabuki M; Komuro S
    Biomed Pharmacother; 2011 Sep; 65(6):451-5. PubMed ID: 21880461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of potential risks of lactic acidosis induction by biguanides in rats.
    Bando K; Ochiai S; Kunimatsu T; Deguchi J; Kimura J; Funabashi H; Seki T
    Regul Toxicol Pharmacol; 2010 Oct; 58(1):155-60. PubMed ID: 20488215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.